Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Aprea Therapeutics ( (APRE) ).
On October 24, 2025, Aprea Therapeutics announced promising early results from their ACESOT-1051 trial for the WEE1 Kinase Inhibitor APR-1051, showing that 3 out of 4 patients achieved stable disease at a 100 mg dose level. The trial, which focuses on heavily pretreated patients with gastrointestinal and gynecologic malignancies, observed disease stabilization in tumors with specific mutations, supporting the mechanistic rationale for APR-1051’s development. The company is encouraged by these findings and is progressing to a higher dose level in the ongoing study.
The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Underperform.
Aprea Therapeutics receives a low overall score due to significant financial challenges, including consistent losses and lack of revenue generation. The company’s strong balance sheet is a positive but is offset by negative cash flows and a reliance on external financing. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on APRE stock, click here.
More about Aprea Therapeutics
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that target specific vulnerabilities in cancer cells while minimizing harm to healthy cells. Their clinical programs include APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both aimed at treating solid tumors.
Average Trading Volume: 65,117
Technical Sentiment Signal: Sell
Current Market Cap: $8.91M
Learn more about APRE stock on TipRanks’ Stock Analysis page.